...
首页> 外文期刊>BMC Molecular Biology >An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
【24h】

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

机译:基于寡核苷酸的polyQ疾病治疗策略评估

获取原文

摘要

Background RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting. Results Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele discrimination but its efficient delivery to cells at low effective concentration still remains a challenge. Conclusions Using three cellular models of polyQ diseases and the same experimental setup we directly compared the performance of different oligonucleotide-based treatment strategies that are currently under development. Based on the results obtained by us and others we discussed the advantages and drawbacks of these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference machinery to show its ability to discriminate between similar sequences differing in either single base substitutions or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts are focused on repeat targeting due to its potentially higher universality.
机译:背景RNA干扰(RNAi)和反义策略为多种疾病(包括由CAG重复扩增引起的聚谷氨酰胺(polyQ)疾病)提供了实验性治疗剂。我们比较了基于寡核苷酸的不同策略沉默导致几种polyQ疾病(包括亨廷顿舞蹈病和两种小脑共济失调,1型和3型)的基因的潜力。这些策略包括非等位基因选择性基因沉默,基因替换,等位基因选择性SNP定位和CAG重复定位。结果使用患者源的polyQ疾病细胞培养模型,我们测试了各种siRNA和反义试剂,并评估了它们的沉默效率和等位基因选择性。我们在RISC诱导的切割位点基于弱G-G或G-U与正常等位基因配对以及强G-C与突变等位基因配对,通过几个针对SNP的siRNA表现出可观的等位基因歧视。在CAG重复靶向试剂中,最强的等位基因识别是通过miRNA样功能性试剂实现的,这些试剂结合至其靶标并抑制其翻译而没有实质性的靶标切割。此外,吗啉代类似物在突变和正常等位基因识别中表现良好,但以低有效浓度有效递送至细胞仍然是一个挑战。结论使用polyQ疾病的三种细胞模型和相同的实验设置,我们直接比较了目前正在开发的基于寡核苷酸的不同治疗策略的性能。基于我们和其他人获得的结果,我们从几个不同的角度考虑了这些策略的优缺点。通过靶向相关基因的特定序列,旨在非等位基因选择性抑制致病基因表达的策略最容易实施,但相关的益处仍不确定。将非等位基因选择性基因沉默与外源正常等位基因的表达相结合的基因替代策略是前者的逻辑扩展,值得进一步探讨。两种等位基因选择性RNAi方法都向细胞RNA干扰机制发起挑战,以展示其区分单碱基取代或重复序列长度不同的相似序列的能力。尽管这两种方法在等位基因识别中都表现良好,但由于其更高的通用性,我们大多数工作都集中在重复定位上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号